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Abstract
Background Although most aneurysmal subarachnoid hemorrhage (aSAH) patients suffer from neuropsychological disabilities,
outcome estimation is commonly based only on functional disability scales such as the modified Rankin Scale (mRS). Moreover,
early neuropsychological screening tools are not used routinely.
Objective To study whether two simple neuropsychological screening tools identify neuropsychological deficits (NPDs), among
aSAH patients categorized with favorable outcome (mRS 0—2) at discharge.
Methods We reviewed 170 consecutive aSAH patients that were registered in a prospective institutional database. We included
all patients graded by the mRS at discharge, and who had additionally been evaluated by a neuropsychologist and/or occupational
therapist using the Montreal Cognitive Assessment (MoCA) and/or Rapid Evaluation of Cognitive Function (ERFC). The
proportion of patients with scores indicative of NPDs in each test were reported, and spearman correlation tests calculated the
coefficients between the both neuropsychological test results and the mRS.
Results Of the 42 patients (24.7%) that were evaluated by at least one neuropsychological test, 34 (81.0%) were rated mRS 0—2
at discharge. Among these 34 patients, NPDs were identified in 14 (53.9%) according to the MoCA and 8 (66.7%) according to
the ERFC. The mRS score was not correlated with the performance in the MoCA or ERFC.
Conclusion The two screening tools implemented here frequently identified NPDs among aSAH patients that were categorized
with favorable outcome according to the mRS. Our results suggest that MoCA or ERFC could be used to screen early NPDs in
favorable outcome patients, who in turn might benefit from early neuropsychological rehabilitation.
Keywords Aneurysmal subarachnoid hemorrhage . Functional outcome . Impairment . Modified Rankin scale .
Multi-dimensional outcome assessment . Neuropsychological outcome
Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-
threatening disease with short- and mid-term mortality of
roughly 40% [1]. In recent years, survival rates have increased
due to improvements in risk factor control, early diagnosis,
and critical care management, as well as in surgical and
endovascular prevention of re-bleeding [2]. While the number
of aSAH survivors is slowly rising, the assessment of patients
with non-fatal outcomes is becoming increasingly relevant
[3].
During the hospital period following aSAH, the outcome of
survivors is often evaluated only by functional grading scales
such as the modified Ranking Scale (mRS) [4] or Glasgow
Outcome Scale (GOS) [5]. Despite their advantages in terms
of standardizing the outcome assessment, some criticism has
been raised regarding their insensitivity to neuropsychological
deficits (NPDs) [6–8]. In fact, NPDs are the most common
form of disabilities after aSAH; nearly half of the independent
patients suffer from these impairments, causing difficulties in
activities of daily living (ADLs) and return to premorbid work
[9–11]. It has been shown that early initiation of appropriate
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rehabilitation after aSAH can decrease the rates of disabilities
[12, 13]. Nevertheless, early-phase screening tools that in-
clude the neuropsychological and psycho-social aspects of
patient outcome are rarely conducted in neurosurgical practice
or clinical trials [14].
In a recent study, Haug Nordenmark et al. [15] concluded
that the majority of early NPDs after aSAH are missed by the
mRS, hence additional assessments should be included in
neurosurgical practice. We aimed to determine whether two
practical screening tools for NPDs can identify early neuro-
psychological impairments, even among aSAH patients cate-
gorized with favorable outcome that might be discharged in-
stead of receiving inpatient rehabilitation. If a screening tool
detected NPDs – even in favorable outcome patients – it could
be considered for implementation in a routine discharge as-
sessment. Diagnosing NPDs would enable initiating appropri-
ate therapy, thereby decreasing long-term morbidity of aSAH.
Material and methods
Patients
We screened a total of 170 consecutive aSAH patients that
were treated at our neurosurgical department, and discharged
between January 2015 and April 2018. aSAH diagnosis was
confirmed with clinical and radiological examinations (com-
puted tomography angiography (CT-A), digital subtraction
angiography (DSA), magnetic resonance angiography (MR-
A) and/or spinal tap). In order to be included in the study,
patients had to be evaluated by the mRS and at least one
additional neuropsychological test before the first hospital dis-
charge after aSAH. Neuropsychological screenings were per-
formed after patients had reached a stable condition (e.g. no
signs of hydrocephalus, no delayed cerebral ischemia (DCI),
no sodium electrolyte disorder), usually in the last days prior
to the hospital discharge.
Information about patients’ age, sex, hypertension (yes/no)
and smoking (yes/no) was collected prospectively on admis-
sion. Information on complications, particularly hydrocepha-
lus, cerebral vasospasm (CVS), DCI and disability outcome
(mRS) were extracted from the institutional patient registry
[16] or added by their retrospective chart review as needed.
Case-severity of aSAH was defined by the World Federation
of Neurosurgical Societies (WFNS) grading scale [17] and the
amount of cisternal hemorrhage (Barrow Neurological
Institute (BNI) scale [18]). In addition, treatment modality
(microsurgical (clipping) vs. endovascular (coiling)) was
recorded.
Patients were excluded if they had missing relevant data or
documented NPDs before aSAH. In addition, those with fatal,
traumatic, non-aneurysmal and perimesencephalic SAH were
also excluded.
Outcome assessments
Based on previous literature [14, 19, 20], the analysis fo-
cused on NPDs; the mRS, which is currently used as the
“gold standard” for disability after a stroke, was used as a
reference variable [21]. The mRS and Montreal Cognitive
Assessment (MoCA) are both recommended by the
National Institute of Health (NIH) and National Institute of
Neurological Disorders and Stroke (NINDS) as valid out-
come measures after aSAH (common data elements (CDE)
working group on unruptured cerebral aneurysms and SAH
[22]). All assessments were made when the patients were
first hospitalized after aSAH.
At hospital discharge, all patients were graded according to
the mRS by resident and faculty neurosurgeons that had been
trained and certified in its use [23]. Since fatal aSAH cases
were excluded, the mRS was used to classify patients into one
of six categories: 0) no symptoms, 1) no significant disabil-
ities, 2) slight disabilities, 3) moderate disabilities, 4) moder-
ately severe disabilities, or 5) severe disabilities. In line with
the definition of the ISAT trial, favorable outcomewas defined
as mRS categories of 0, 1 and 2 [24].
The MoCA-based evaluations were performed by neuro-
psychologists trained in its use, following the standard oper-
ating procedures for test conduction and scoring [25]. The
MoCA is a well-studied, single-page screening tool for
NPDs after aSAH that takes around 10—20 min to perform
and uses a point-based system to evaluate patients’ abilities of
executive functions, naming, attention, recall, abstraction and
orientation [14, 19, 26, 27]. One additional point is added for
patients with fewer than 12 years of education. From a total of
30 points, a score of <26 has been defined as a score that
indicates NPDs [28].
The Rapid Evaluation of Cognitive Function (ERFC =
Évaluation Rapide des Fonctions Cognitives [29]) is another
screening tool for the evaluation of NPDs in the aSAH popu-
lation. Although it has been studied less than the other screen-
ing tools, its reliability (intra-class correlation coefficient =
0.87, p < 0.001) and concurrent validity with the Mini-
Mental State Examination (MMSE) test has been demonstrat-
ed (0.91, p < 0.001) [30]. The test contains 12 items that assess
spatial orientation, attention span, immediate and deferred
memory, reasoning and judgment, mental calculation, com-
prehension, repetition, denomination, execution of a written
order, apraxia, verbal fluency, visual decoding and writing.
From a total of 50 points, a score of <46 has been defined as
a score that indicates NPDs [31]. The ERFC-based evalua-
tions were performed by fully-trained occupational therapists.
Statistical analyses
Baseline patient characteristics were summarized using mean
values with standard deviation in continuous variables,
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whereas categorical variables were reported using frequencies
with proportions as a percentage. The differences between
included and excluded patients were evaluated using indepen-
dent t-tests (continuous variables) and Fisher’s exact tests (cat-
egorical variables). Descriptive statistics were used to report
the proportion of patients categorized with favorable outcome
that showed NPDs according to the MoCA or ERFC. In ad-
dition, NPDs were investigated separately in groups with
good (mRS = 1) and excellent (mRS = 0) outcome. The rela-
tionship between the reference variable (mRS) and each of the
NPD screening tools (MoCA and ERFC) was calculated with
Spearman’s correlation coefficients. The strength of the corre-
lation was categorized as weak (0.10–0.29), moderate (0.30–
0.49) or strong (0.50–1.00) [32]. Linearity was analyzed with
a linear regression model (Coefficient and 95% confidence
interval (CI)), while the influence of age and sex were adjusted
with multiple linear regression. Relationships are graphically
presented by scatter plots with fitted regression lines and 95%
CIs. Analyses were performed with Stata version 14.2 (Stata
Corp, College Station, TX). p values <0.05 were considered
statistically significant.
Results
Of the 170 aSAH patients, 42 (24.7%) performed at least one
out of the two specific NPD tests during hospitalization, and
thus were included in our analysis. The specific proportions
for the MoCA and ERFC were 18.2% (n = 31) and 9.4% (n =
16), respectively. On average, the patients included in the
analysis showed milder aSAHs (p = 0.002), hospitalization
periods that were six days shorter (p = 0.011), and more fa-
vorable hospital discharge status (p = 0.024) compared to
aSAH patients who were evaluated only by the mRS
(Table 1). NPD screenings were performed on average sixteen
(interquartile range (IQR) = 13–21) days after aSAH whereas
median difference to mRS assessments was two (IQR = 0–5)
days. None of the analyzed patients had excellent functional
outcome (mRS = 0) at discharge.
MoCA and mRS
Of the 31 patients with MoCA measurements, nine were
categorized with good outcome status (mRS = 1) and 26 with
favorable outcome status (mRS = 0–2) at hospital discharge.
The prevalence of NPDs was high among these patients: of
the nine patients with good outcome and the 26 with favor-
able outcome, six (66.7%) and 14 (53.8%), respectively, had
neuropsychological impairments according to the MoCA.
The correlation between the MoCA and mRS was non-
significant (Fig. 1; Table 2).
ERFC and mRS
Of the 16 patients with ERFC measurements, nine were cate-
gorized with good outcome status (mRS = 1) and 12 with
favorable outcome status (mRS = 0–2) at hospital discharge.
In line with the results of theMoCA, seven of the nine patients
with good outcome (77.8%) and eight of the 12 with favorable
outcome (66.7%) had NPDs according to the ERFC. Similar
to the MoCA, there was no correlation between the ERFC and
mRS, as hypothesized (Fig. 2; Table 2).
Discussion
The results of this preliminary and retrospective study suggest
that the MoCA and ERFC are valuable instruments for the
early detection of NPDs in aSAH patients that are in relatively
good condition and might be considered for home discharge
instead of inpatient rehabilitation. We found NPDs in more
than half of the patients that were categorized with favorable
outcome according to the mRS (using the described cut-off
values for cognitive impairment). NPDs and mRS scores
showed no correlation, suggesting that functional and neuro-
psychological outcomes should be assessed independently. As
discharge status and the perceived disabilities at discharge are
key indicators for the choice of proper rehabilitation, the sim-
ple outcome screening tools examined here would likely help
to recognize those aSAH patients who would benefit from a
more detailed neuropsychological workup and early neuro-
psychological rehabilitation.
The favorable outcome status has generally included mRS
categories 0–2. However, in order to exclude patients with
slight disabilities, a more strict definition has been proposed
for this status, which only includes mRS categories of 0 and 1
[33]. Our study shows that the mRS is unable to detect neu-
ropsychological impairments, regardless of the cut-off range.
In fact, according to the MoCA and ERFC, the proportions of
NPDs were even higher (66.7% and 77.8%, respectively) in
aSAH patients with goodmRS outcome (mRS = 1). This find-
ing suggests that even when the function of aSAH patients
appears similar to the pre-ictal level, simple but validated neu-
ropsychological screening tools can reveal impairments that
might otherwise remain unnoticed. Prior works from Haug
Nordenmark et al. [15] elucidated a significant mismatch be-
tween an – apparently – favorable outcome on the mRS and
severely impaired global cognitive function in the acute phase
(close to discharge from the hospital). It is possible that with
ongoing recovery over time the cognitive scores and disability
grading scales align better, however. At three months after the
ictus, Wong et al. [27] demonstrated a moderate negative cor-
relation between the mRS and Chinese version of the MoCA
(−0.413, p < 0.001). One drawback of both our current and the
previous study from Haug Nordenmark et al. [15] are the
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limited sample sizes, which cannot exclude the possibility that
the analyses were underpowered to detect a significant corre-
lation. Still, the impressive contrast between relatively mild
functional impairment and severely reduced cognitive abilities
outlined in both studies leave little room for doubt that the
mRS does not qualify to judge upon the need for neuropsy-
chological rehabilitation after hospital discharge.
It has been 25 years since Hütter and Gilsbach highlighted
that six months post-aSAH, neuropsychological deficits were
frequent even among SAH patients that seemed to fare well.
[6] Since then, similar findings have been reported by several
other research groups [11, 34, 35]. However, we found only
one study that evaluated the incidence of NPDs in patients
with favorable functional outcome at the early stages after
aSAH. Specifically, HaugNordenmark et al. [15] reported that
57% of all discharged aSAH patients had a poor cognitive
outcome. Similar to our results, nearly half of the cases were
still graded with favorable outcome (mRS 0—2). Their con-
clusion was that in addition to the mRS, another neuropsycho-
logical screening tool should be used to identify early NPDs
after aSAH. However, the authors did not suggest any specif-
ic, short and practical screening tool – which is what we have
provided in the present paper.
One of our screening tools, the MoCA, has also been con-
sidered by the NIH/NINDS CDE as a first-line neuropsycho-
logical screening tool among aSAH patients [22]. The sensitiv-
ity for milder NPDs is reportedly high, and the tool has there-
fore been graded as superior to other commonly used cognitive
screening tools, such as MMSE [19, 26]. In fact, in the recent
study of 337 aSAH patients, Eagles et al. [35] concluded that
although MMSE scores varied in favorable outcome patients
(mRS 0—2) 12 weeks after aSAH, more sensitive variables,
Table 1 Characteristics of 170 consecutive aneurysmal subarachnoid
hemorrhage patients that were discharged after aneurysmal subarachnoid
hemorrhage. The table illustrates (by bolded text) that patients included in
this study had lighter World Federation of Neurosurgical Societies
admission scores and developed hydrocephalus less frequently.
Accordingly, their hospitalization was around six days shorter and their
discharge status was more favorable
No NPD measurement (excluded) MoCA and/or ERFC measured (included) p value
Age, mean (SD) 55.5 (12.6) 55.8 (11.3) 0.89
Sex, male (%) 47 (36.7) 12 (28.6) 0.36
Hypertension, n (%) 42 (32.8) 16 (38.1) 0.58
Smoker, n (%) 40 (31.3) 19 (45.2) 0.13
WFNS, n (%)
I
II
III
IV
V
44 (34.4)
24 (18.8)
6 (4.7)
29 (22.7)
25 (19.5)
25 (59.5)
9 (21.4)
2 (4.8)
6 (14.3)
0 (0)
0.002
Treatment, n (%)
Microsurgical (clipping)
Endovascular (coiling)
66 (51.6)
62 (48.4)
17 (40.5)
25 (59.5)
0.22
Cerebral vasospasm, n (%) 49 (38.3) 20 (47.6) 0.37
Delayed cerebral ischemia, n (%) 27 (21.1) 10 (23.8) 0.83
Hydrocephalus, n (%) 84 (65.6) 17 (40.5) 0.006
BNI-scale, n (%)
1)
2)
3)
4)
5)
5 (3.9)
10 (7.8)
42 (32.8)
52 (40.6)
19 (14.8)
0 (0)
3 (7.1)
21 (50.0)
15 (35.7)
3 (7.1)
0.26
Length of hospitalization in days, mean (SD) 29.1 (16.1) 23.6 (10.2) 0.011
mRS at discharge, n (%)
0–2 (favorable outcome)
3–5 (unfavorable outcome)
78 (60.9)
50 (39.1)
34 (81.0)
8 (19.0)
0.024
n = 128 (100%) n = 42 (100%)
NPD = neuropsychological deficit
MoCA=Montreal Cognitive assessment
ERFC= The Rapid Evaluation of Cognitive Function
WFNS =World Federation of Neurosurgical Societies
BNI = Barrow Neurological Institute
mRS =modified Rankin Scale
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such as the MoCA, should be used to detect milder NPDs
among these patients. Similarly, three studies by Wong et al.
have investigated the relationship between the mRS andMoCA
[20, 27, 36]. The first study revealed a low association between
the MoCA (measured at a subacute phase (2—4 weeks) after
aSAH) and unfavorable functional outcome (mRS 3—5) at one
year [36]. In the second study, a moderate negative correlation
was found between the Chinese version of theMoCA andmRS
three months after aSAH [27]. In the third study, only an excel-
lent outcome (mRS = 0) was associated with the MoCA at one
year [20]. Similar to our findings, these results emphasize that
the MoCA qualifies as a rational tool to screen the neuropsy-
chological function in aSAH patients. Moreover, our ERFC
findings are in line with those of the MoCA. However, as the
literature behind the ERFC is limited, we believe that more data
is needed to confirm its ability to reliably diagnose SAH-
associated NPDs.
Implications for clinical practice and research
After aSAH, NPDs are frequent when routinely screened for,
and can encompass executive functions (up to 76% of aSAH
patients), memory (up to 61%), language (up to 76%) and
sleeping (up to 45%) [10]. These impairments have implica-
tions for the affected patients’ ADLs, ability to work and qual-
ity of life [9, 10]. Self-reported impairments may be even more
frequent: Passier et al. [37] found that 95% of aSAH patients
reported cognitive or emotional complaints that caused trou-
bles in ADLs three months after the ictus. Intensive and timely
rehabilitation can effectively decrease the amount of depen-
dency andmitigate impairments, even among patient with poor
grading at admission [12, 13]. Considering the high prevalence
of NPDs as indicated in this study, an appropriate outcome
assessment before hospital discharge will likely guide patients
to adequate rehabilitation, thereby reducing individual disabil-
ities and positively affecting patients’ return to independent
ADLs. Additionally, the reduction of disabilities might miti-
gate the economic burden of aSAHs, for example by helping
otherwise healthy, working-age individuals to return to work
[38].
Multidimensional outcome assessment appears similarly
important for research: it has been suggested that the lack of
appropriate outcome measures is one of the reasons for the
failure of many aSAH outcome trials [39]. In addition, it is
Fig. 1 Correlation between the
MoCA and mRS
Table 2 Correlations between neuropsychological test patterns and the mRS. None of the analyzed patients had excellent outcome (mRS = 0) at
discharge
Neuropsychological
variable
Number of cases Correlation coefficients
with mRS
Linearity with mRS Prevalence of NPD in patients with good (mRS = 1) and
favorable (mRS = 0—2) outcome, n (%)
ρ (95% CI) p value p value mRS 1 mRS 0—2
MoCA 31 −0.24 (−0.62–0.14) 0.208 0.052 6 of 9 (66.7) 14 of 26 (53.8)
ERFC 16 0.050 (−0.46–0.56) 0.849 0.56 7 of 9 (77.8) 8 of 12 (66.7)
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important to implement a more comprehensive and standard-
ized outcome assessment as early as possible in order to iden-
tify patients for effective and early rehabilitation after aSAH.
Prospective, multi-center research applying the MoCA as a
primary endpoint is currently conducted in Switzerland [25].
In addition, multi-national therapeutic trials enrolling aSAH
patients apply neuropsychological screening tools as second-
ary outcomes [40]. Hence, the implication of a neuropsycho-
logical outcome assessment provides the potential for many
areas to benefit.
The neuropsychological screening tools presented here
may even be routinely used by the neurosurgical staff, name-
ly physicians, physician-assistants or nurses that are trained
in the application of such tools. The two screening tools
examined in our study appear to have a high sensitivity for
detecting NPDs, are relatively fast to conduct, and simple
enough to use for screening purposes. Given that neuropsy-
chological resources are limited in the majority of neurosur-
gical departments globally, an approach that screens aSAH
patients with favorable outcome before discharge would
seem reasonable. Of course, additional workups by profes-
sional neuropsychologists should be organized in cases
where the neuropsychological screening is abnormal.
Overall, we believe that the population of aSAH patients
would benefit from such an approach.
Strengths and limitations
This study provides new data on the association between the
mRS, which is currently the “gold standard” in outcome as-
sessment for stroke and SAH, and more in-depth functional
and neuropsychological outcome. It confirms previously
reported relationships and adds new data to the existing body
of literature. In particular, this study does reconfirm previously
described relationships in a modern, contemporary series
treated according to modern and potentially less traumatizing
endovascular and microsurgical techniques. While the MoCA
is a relatively well studied and recommended tool for outcome
evaluation after aSAH [22], much less experience has been
accumulated for the ERFC in this setting. Similar to earlier
studies, the conclusions drawn from our analyses are limited
by the small sample size and the retrospective nature of the
study. This – and the fact that both the MoCA and ERFC are
merely screening tools – is why we desisted from more de-
tailed, domain-specific analysis of NPD, as was done in other
studies [15] before for the acute setting. In addition, since all
our consecutively admitted 170 aSAH patients were not
assessed routinely by NPD screening tools, suspicion of
NPDs may have had an effect on the patient selection for
additional MoCA or ERFC screening. Nevertheless, the con-
sistency between our results and those from prior studies
strengthens our confidence in the findings reported here.
Conclusion
Neuropsychological impairments were frequently identified
among aSAH patients that were categorized with favorable
outcome according to the mRS. The current work highlights
this previously described phenomenon in a contemporary se-
ries of aSAH patients managed according to modern guide-
lines.Moreover, the data show that by employing a reasonably
short and inexpensive neuropsychological screening tool, a
substantial proportion of patients is identified who might
Fig. 2 Correlation between the
ERFC and mRS
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benefit from early neuropsychological rehabilitation, even
though they appear to fare well. Further studies are necessary
to evaluate the actual long-term benefit of such an early
screening for the patient.
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